ArticleJournal of the American Academy of Child and Adolescent Psychiatry2021
Editorial: Precision Medicine in Neurotherapeutics for Attention-Deficit/Hyperactivity Disorder.
Article in Journal of the American Academy of Child and Adolescent Psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- External trigeminal nerve stimulation versus sham stimulation for attention deficit hyperactivity disorder in children and adolescents aged 7-17 years: study protocol for a pilot and feasibility randomized clinical trial.European child & adolescent psychiatry · 2025Article
- Research progress of tDCS in the treatment of ADHD.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Noninvasive Brain Stimulation for Improving Cognitive Deficits and Clinical Symptoms in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.Brain sciences · 2024Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
Noninvasive brain stimulation is a novel treatment avenue for attention-deficit/hyperactivity disorder (ADHD). The advantages over pharmacological treatment are relatively minimal and transient side-effects, which make it a treatment preferred by patients and parents. Neurostimulation can furthermore target key neurobiological abnormalities established over decades of neuroimaging research. Trigeminal nerve stimulation (TNS) is the only neuromodulation and device-based nonpharmacological treatment recently licensed for children with ADHD by the US Food and Drug Administration. This was based on a double-blind sham-controlled proof-of-concept trial of 4 weeks of TNS in 62 children, who showed a reduction of ADHD symptoms with an effect size of 0.5, similar to the results with second-line nonstimulant pharmacological treatment.
Indexed as
Identifiers
33264662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.